Journey Medical Corp (DERM)
3.50
+0.10
(+2.94%)
USD |
NASDAQ |
Apr 25, 16:00
3.48
-0.02
(-0.57%)
After-Hours: 20:00
Journey Medical Cash from Financing (TTM): -4.804M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -4.804M |
September 30, 2023 | -23.07M |
June 30, 2023 | -8.057M |
March 31, 2023 | 5.142M |
December 31, 2022 | 16.46M |
Date | Value |
---|---|
September 30, 2022 | 47.31M |
June 30, 2022 | 54.49M |
March 31, 2022 | 54.99M |
December 31, 2021 | 53.02M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-23.07M
Minimum
Sep 2023
54.99M
Maximum
Mar 2022
21.72M
Average
16.46M
Median
Dec 2022
Cash from Financing (TTM) Benchmarks
Fortress Biotech Inc | 32.74M |
Puma Biotechnology Inc | 0.00 |
GT Biopharma Inc | 6.268M |
FibroGen Inc | 122.75M |
Outlook Therapeutics Inc | 5.120M |